iLite® FGF-21 Assay Ready Cells
BM3071
This iLite® FGF-21 reporter assay provides cell-based measurement of FGF-21 signaling, supporting metabolic research and development of FGF-21 analogs or mimetics.
- High sensitivity and large dynamic range
- "Assay-ready" format for rapid and convenient use
- Reproducible and biologically relevant results
- Reduced assay variability and higher reproducibility compared to cells in culture
- Normalization of cell counts and serum matrix effects using a second reporter gene
Product Overview
iLite® FGF21 Assay Ready Cells are based on the human embryonic kidney cell line, HEK293, and have been genetically engineered and optimized to be responsive to human FGF21 and analogues of human FGF21 by specific and proportional expression of Firefly Luciferase.
For drug development in the field of metabolic disorders, iLite FGF21 Assay Ready Cells perfectly complements iLite Insulin Assay Ready Cells for measurement of potency and immunogenicity.
Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under the control of a constitutive promotor.
FOR RESEARCH USE ONLY
How it works
The function of iLite assays
iLite cells have receptors on the cell surface that can bind to the marker under study.
What's in the box?
>250 µL of Assay Ready Cells suspended in cryoprotective medium.
Specifications
| Product code | BM3071 |
| Assay target | FGF-21 |
| Size | 1 vial corresponding to one 96 well plate |
| Technology | Cell-based reporter gene assay |
| Detection system | Luminescence |
| Regulatory status | Research Use Only |
Documents
Application Note
Downloads
Navigating the Complexities of Cell-based Assays in GMP QC Testing: The Journey to Robust Assays
Read post
The Value of Assay-Ready Cells in Providing Biologically Relevant Data for Robust Therapeutic Develo...
Read post
How Biosimilars Are Expanding Options for Patient Care
Read post
Biosimilar Development: Experts Discuss Analytical Characterization Toolkits for Antibody Therapeuti...
Read post
The Future of Drug Development for Complex Pathologies: Versatile Cell-based Assays and Customizable...
Read post
